I’ll concede that there may be modest bias against REDUCE-IT among some of the top biotech people I follow on Twitter insofar as few, if any, of them predicted success. The former head of R&D for a Big Pharma (and someone I follow on Twitter) told me this in August:
However, I wouldn’t knock Matt Herper, who is one of the best biotech beat writers. Matt doesn’t scrutinize technical papers on his own; rather, he calls experts in the field for comment, as he did in this instance. Some of the posters on the AMRN iHub board are going wacko with their accusations against Matt and others.